Company profile for Spur Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Spur Therapeutics formerly known as Freeline is a privately-held clinical-stage biotechnology company focused on AAV based gene therapy targeting the liver. Our vision is to create better lives for people suffering from chronic systemic diseases using the potential of gene therapy as a one-time curative treatment. Freeline is headquartered in the UK and has operations in Germany and the US.Targeting the liver with our novel ge...
Spur Therapeutics formerly known as Freeline is a privately-held clinical-stage biotechnology company focused on AAV based gene therapy targeting the liver. Our vision is to create better lives for people suffering from chronic systemic diseases using the potential of gene therapy as a one-time curative treatment. Freeline is headquartered in the UK and has operations in Germany and the US.Targeting the liver with our novel gene therapy platform enables us to treat a wide range of chronic diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Stevenage, Herefordshire
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/07/3162226/0/en/Spur-Therapeutics-Presents-Updated-Phase-1-2-Data-on-Its-Gene-Therapy-Candidate-in-Gaucher-Disease-at-ESGCT-32nd-Annual-Congress.html

GLOBENEWSWIRE
07 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159368/0/en/Spur-Therapeutics-to-Present-New-Clinical-Data-on-Its-Gene-Therapy-Candidate-in-Gaucher-Disease-at-Upcoming-ESGCT-Annual-Congress.html

GLOBENEWSWIRE
01 Oct 2025

https://www.globenewswire.com/news-release/2025/06/06/3095043/0/en/Spur-Therapeutics-Presents-Positive-New-Preclinical-Data-on-Its-Gene-Therapy-Candidate-for-GBA1-Parkinson-s-Disease-at-2025-GBA1-Meeting.html

GLOBENEWSWIRE
06 Jun 2025

https://www.globenewswire.com/news-release/2025/05/27/3088548/0/en/Spur-Therapeutics-Publishes-Preclinical-Proof-of-Concept-Data-for-FLT201-its-Clinical-Stage-Gene-Therapy-Candidate-in-Gaucher-Disease.html

GLOBENEWSWIRE
27 May 2025

https://www.globenewswire.com/news-release/2025/05/15/3081894/0/en/Spur-Therapeutics-Presents-Positive-New-Clinical-and-Preclinical-Data-on-Its-Gene-Therapy-Programs-at-ASGCT-28th-Annual-Meeting.html

GLOBENEWSWIRE
15 May 2025

https://www.globenewswire.com/news-release/2025/05/01/3072285/0/en/Spur-Therapeutics-to-Participate-in-Citizens-JMP-2025-Life-Sciences-Conference.html

GLOBENEWSWIRE
01 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty